← board
TLPPF
distress 0/10 · well-funded / low risk$10.41-1%today-35% from 52w high
Revenue
$804M
Liquidity
$146M
Runway
—
Shares 1y
0%
Price & events
+39.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-0.9%
1W
+3.7%
1M
-0.9%
3M
+39.0%
6M
-34.9%
1Y
-20.5%
2Y
+159.0%
5Y
+247.0%
All
Overview
- Market Cap
- $3.53B
- Enterprise Value
- $3.78B
- Volume
- 300
- 52 Week Range
- $6.50 – $16.00
- Total Shares
- 338.78M
- Float Shares
- 272.81M
- % Held by Insiders
- 16.90%
- % Held by Institutions
- 32.57%
- RVOL
- 0.05x
- Beta
- 0.63
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (1)
- ILLUCCIXGALLIUM GA-68 GOZETOTIDE2021 · Prescription
Capital structure — dilution & financing
Shares out: 338,777,049 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.